Thalidomide: Focus on its employment in rheumatologic diseases

Clinical and Experimental Rheumatology

Volumn 20, Issue 5, 2002, Pages 709-718

  Ossandon, Alejandra ^a   Cassará, Emanuele Antonio Maria ^a   Priori, Roberta ^a   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Auto immune disorders; Beh et's disease; Rheumatoid arthritis; Systemic lupus erythematosus; Thalidomide

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BROMOCRIPTINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; ETANERCEPT; GOLD; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; PENTOXIFYLLINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AMENORRHEA; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BEHCET DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEVER; HUMAN; IMMUNOMODULATION; JUVENILE RHEUMATOID ARTHRITIS; MAINTENANCE THERAPY; NAUSEA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SOMNOLENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENESIS; URTICARIA; VERTIGO;

ABNORMALITIES, DRUG-INDUCED; ARTHRITIS, RHEUMATOID; BEHCET SYNDROME; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036708877     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. MELLIN GW, KATZENSTEIN M: The saga of thalidomide. N Engl J Med 1962; 267: 1184-93; 1238-44.
2. MCBRIDE WG: Thalidomide and congenital abnormalities. Lancet 1961; I: 1358.
3. LENTZ W: Thalidomide and congenital abnormalities. Lancet 1962; I: 45.
4. SHESKIN J: Thalidomide in the treatment of lepra reactions. Clin Pharm Therap 1965; 6: 303-6.
5. TAYLOR PC: Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 2001; 13: 164-9.
6. KAM LY, TARGAN SR: TNF-alpha antagonists for the treatment of Crohn's disease. Expert Opin Pharmacother 2000; 1: 615-22.
7. GOOSSENS PH, VERBURG RJ, BREEDVELD FC: Remission of Behcet's syndrome with tumor necrosis factor alpha blocking therapy. Ann Rheum Dis 2001; 60: 637.
8. HASSARD PV, BINDER SW, NELSON V, VASILIAUSKAS EA: Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 2001; 120: 995-9.
9. ROBERTSON LP, HICKLING P: Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology 2001; 40: 473-4.
10. SFIKAKIS PP. THEODOSSIADIS PG, KATSIARI CG, KAKLAMANIS P, MARKOMICHELAKIS NN: Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295-6.
11. REIFF A, TAKEI S, SADEGHI S et al.: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411-5.
12. STEPHENS T, BRYNER R: Dark Remedy: the impact of Thalidomide and its Revival as a Vital Medicine. Cambridge, Mass. Perseus, 2001.
13. SCHUMACHER H, SMITH RL, WILLIAMS RT: The metabolism of thalidomide: The fate of Thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965; 25: 324-7.
14. Link to Thalidomide's approved label: THALOMID (Thalidomide) capsules. Washington (DC:) US Food and Drug Administration/CTEP, 1998.
15. FAURE M, THIVOLET J, GAUCHERAND M: Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 1980; 269: 275-80.
16. BARNHILL RL, DOLL NJ, MILLIKAN LE, HASTINGS RC: Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984; 11: 814-9.
17. HASTING RC: Kellersberger Memorial Lecture 1979: Immunosuppressive/anti inflammatory thalidomide analogues. Ethiop Med J 1980; 18: 65-71.
18. MIYACHI Y, OZAKI M, UCHIDA K, NIWA Y: Effects of thalidomide on the generation of oxygen intermediates by zymosan-stimulated normal polymorphonuclear leukocytes. Arch Dermatol Res 1982; 274: 363-7.
19. MIYACHI Y. A possible mechanism of action of thalidomide on rheumathoid arthritis. Arthritis Rheum 1985; 28: 836.
20. NIELSEN H, BENNIKE T: Thalidomide enhances defective monocyte function in lepromatous leprosy. Lancet 1984; 2: 98-9.
21. SAMPAIO EP, SARNO EN, GALILLY R, COHN ZA, KAPLAN G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
22. KLAUSNER JD, FREEDMAN VH, KAPLAN G: Thalidomide as an anti-TNF-alpha inhibitor: implication for clinical use. Clin Immunol Immunopathol 1996; 81: 219-23.
23. MOREIRA AL, SAMPAIO EP, ZMUIDZINAS A, FRINDT P, SMITH KA, KAPLAN G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80.
24. GEITZ H, HANDT S, ZWINGENBERGER K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31: 213-21.
25. WALCHNER M, MESSER G, WIERENGA EA: Reconstitution of transcription factor binding to the conserved lymphokine elemento and down-regulation of NF-k B activity after thalidomide treatment of systemic lupus erythematosus Arch Dermatol Res 1995; 287: 347.
26. SAMPAIO EP, KAPLAN G, MIRANDA A, NERY JA, MIGUEL CP, VIANA SM, SARNO EN: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408-14.
27. TRAMONTANA JM, UTAIPAT U, MOLLOY A, et al.: Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.
28. WOLKENSTEIN P, LATARJECT J, ROUJEAU JC, et al.: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-9.
29. JACOBSON JM, GREENSPAN JS, SPRITZLER J, et al.: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336: 1487-93.
30. DEAN GS, TYRRELL-PRICE J, CRAWLEY E, ISENBERG DA: Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000; 59: 243-51.
31. JACOB CO, FRONEK Z, LEWIS GD, KOO M, HANSEN JA, MCDEVITT HO: Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990; 87: 1233-7.
32. LEE SH, PARK SH, MIN JK, et al.: Decreased tumour necrosis factor-beta production in TNFB2 homozygote: An important predisposing factor of lupus nephritis in Koreans. Lupus 1997; 6: 603-9.
33. HERRERA-HESPARZA R, BARBOSA-CISNEROS O, VILLALOBOS-HURTADO R, AVALOS-DIAZ E: Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus 1998; 7: 154-8.
34. KEENAN RJ, EIRAS G, BURCKART GJ, et al.: Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. Transplantation 1991; 52: 908-10.
35. CHUONG PH, GALONS H, VOISIN J, et al.: In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxy Thalidomide, alone and in combination with cyclosporin A. Int J Immunopharmacol 1997; 19: 289-96.
36. FERNANDEZ LP, SCHLEGEL PG, BAKER J, CHEN Y, CHAO NJ: Does thalidomide affect IL-2 response and production? Exp Hematol 1995; 23: 978-85.
37. HASLETT PA, CORRAL LG, ALBERT M, KAPLAN G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-92.
38. GAD SM, SHANNON EJ, KROTOSKI WA, HASTINGS RC: Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev 1985; 56: 35-9.
39. McHUGH SM, RIFKIN IR, DEIGHTON J, et al.: The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160-7.
40. ATRA E, SATO EI: Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993; 11: 487-93.
41. SHANNON EJ, MIRANDA RO, MORALES MJ, HASTINGS RC: Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol 1981; 13: 553-62.
42. D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5.
43. KRUSE FE, JOUSSEN AM, ROHRSCHNEIDER K, BECKER MD, VOLCKER HE: Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 461-6.
44. GUTMAN M, SZOLD A, RAVID A, LAZAUSKAS T, MERIMSKY O, KLAUSSNER JM: Failure of thalidomide inhibit tumor growth and angiogenesis in vivo. Anticancer Res 1996; 16: 3673-7.
45. BAUER KS, DIXON SC, FIGG W: Inhibition of angiogenesis by thalidomide requires metabolic activation which is species-dependent. Biochem Pharmacol 1998; 55: 1827-34.
46. KARIM MY, RUIZ-IRASTORZA G, KHAMASHTA MA, HUGHES GRV: Update on therapy-thalidomide in the treatment of lupus. Lupus 2001; 10: 188-92.
47. BARBA RUBIO J, FRANCO GONZALEZ F: Fixed lupus erythematosus (its treatment with thalidomide). Med Cutan Ibero Lat Am 1977; 5: 279-85.
48. SAMSOEN M, GROSSHANS E, BASSET A: La Thalidomide dans le traitement du lupus erythemateux chronique (L.E.C.). Ann Dermatol Venereol 1980; 107: 515-23.
49. LEVI L, SAGGIORATO F, CRIPPA D: Attività e meccanismo d'azione della talidomide in 18 pazienti affetti da lupus eritematoso discoide fisso. G Ital Dermatol Venereol 1980; 115: 471-5.
50. KNOP J, HAPPLE R, VAKILZADECH F, MACHER E: Treatment of lupus erythematosus profundus with thalidomide. Arch Dermatol Res 1981; 270: 229.
51. NAAFS B, BAKKERS EJ, FLINTERMAN J, FABER WR: Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol 1982; 107: 83-6.
52. HASPER MF: Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Arch Dermatol 1983; 119: 812-5.
53. KNOP J, BONSMANN G, HAPPLE R, et al.: Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983; 108: 461-6.
54. GROSSHANS E, ILLY G: Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 1984; 23: 598-602.
55. BESSIS D, GUILLOT B, MONPOINT S, DANDURAND M, GUILHOU JJ: Thalidomide for systemic lupus erythematosus. Lancet 1992; 339: 549-50.
56. HAWKINS DF: Thalidomide for systemic lupus erythematosus. Lancet 1992; 339: 1057.
57. BURROWS NP: Diagnosis and management of systemic lupus erythematosus. Thalidomide modifies disease. BMJ 1993; 307: 939-40.
58. STEVENS RJ, ANDUJAR C, EDWARDS CJ, et al.: Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997; 36: 353-9.
59. SATO EI, ASSIS LS, LOURENZI VP, ANDRADE LE: Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras 1998; 44: 289-93.
60. DUONG DJ, SPIGEL GT, MOXLEY RT 3rd, GASPARI AA: American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999; 135: 1079-87.
61. KYRIAKIS KP, KONTOCHRISTOPOULOS GJ, PANTELEOS DN: Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 2000; 39: 218-22.
62. WALCHNER M, MEURER M, PLEWIG G, MESSER G: Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 2000; 39: 383-8.
63. ORDI-ROS J, CORTES F, CUCURULL E, MAURI M, BUJAN S, VILARDELL M: Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 2000; 27: 1429-33.
64. BRENNAN FM, MAINI RN, FELDMANN M: TNF alpha a pivotal role in rheumatoid arthritis ? Br J Rheumatol 1992; 31: 293-8.
65. CAMUSSI G, LUPIA E: The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998; 55: 613-20.
66. GUTIERREZ-RODRIGUEZ O: Veinte años despues: Talidomida, nuevo agente antirreumatico. Comunicacion preliminar. Colombia Med 1981; 12: 176-9.
67. GUTIERREZ-RODRIGUEZ O: Thalidomide: a promising new treatment for rheumatoid arthritis. Arthritis Rheum 1984; 27: 1118-21.
68. GUTIERREZ-RODRIGUEZ O, STARUSTABACAL P, GUTIERREZ-MONTES O: Treatment of refractory rheumatoid arthritis - The thalidomide experience. J Rheumatol 1989; 16: 158-63.
69. HUIZINGA TW, DIJKMANS BA, VAN DER VELDE EA, VAND DE POUW KRAAN TC, VERWEIJ CL, BREEDVELD FC: An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Rheum Dis 1996; 55: 833-6.
70. HAN J, THOMPSON P, BEUTLER B: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391-4.
71. MAKSYMOWYCH WP, AVINA-ZUBIETA A, LUONG MH, RUSSELL AS: An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995; 22: 625-9.
72. KEESAL N, WASSERMAN MJ, BOOKMAN A, LAPP V, WEBER DA, KEYSTONE EC: Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol 1999; 26: 2344-7.
73. SCOVILLE CD: Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2001; 19: 360-1.
74. LEHMAN TJA, STRIEGEL KH, ONEL KB: Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr 2002; 140: 125-7.
75. BAND D: Treatment of Behçet's disease. Yonsei Med J 1997; 38: 401-10.
76. MASCARO JM, LECHA M, TORRAS H: Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis. Arch Dermatol 1979; 115: 636-7.
77. SAYLAN T, SALTIK I: Thalidomide in the treatment of Behçet's syndrome. Arch Dermatol 1982; 118: 536.
78. TORRAS H, LECHA M, MASCARO JM: Thalidomide in the treatment of aphtosis and Behçet's disease. 4 years' experience. Med Cut Ibero Lat Am 1982; 10: 103-12.
79. HAMZA MH: Treatment of Behçet's disease with thalidomide. Clin Rheumatol 1986; 5: 365-71.
80. HAMZA M: Behçet's disease, palmoplantar pustolosis and HLA B-27: Treatment with thalidomide. Clin Exp Rheumatol 1990; 8: 427.
81. LARSSON H: Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217). J Int Med 1990; 228: 405-7.
82. POSTEMA PT, DEN HAAN P, VAN HAGEN PM, VAN BLANKENSTEIN M: Treatment of colitis in Behçet's disease with thalidomide. Eur J Gastroenterol Hepatol 1996; 8: 929-31.
83. SHIMIZU T, EHRILICH GE, INABA G, HAYASHI K: Behçet disease (Behcet syndrome). Semin Arthritis Rheum 1979; 8: 223-60.
84. GARDNER-MEDWIN JM, SMITH NJ, POWELL RJ: Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: Use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53: 828-32.
85. SHEK LP, LEE YS, LEE BW, LEHMAN TJ: Thalidomide responsiveness in an infant with Behcet's syndrome. Pediatrics 1999; 103: 1295-7.
86. BRIK R, SHAMALI H, BERGMAN R: Successful thalidomide treatment of severe infantile Behçet disease. Pediatr Dermatol 2001; 18: 143-5.
87. KARI JA, SHAH V, DILLON MJ: Behçet's disease in UK children: Clinical features and treatment including thalidomide. Rheumatology (Oxford) 2001; 40: 933-8.
88. RANSELAAR CG, BOONE RM, KLUIN-NELEMANS HC: Thalidomide in the treatment of neuro-Behçet's syndrome. Br J Dermatol 1986; 115: 367-70.
89. HAMURYUDAN V, MAT C, SAIP S, et al.: Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443-50.
90. STAMBE C, WICKS IP: TNF alpha and response of treatment-resistant adult-onset Still's disease to thalidomide. Lancet 1998; 352: 544-5.
91. BRAUN J, BOLLOW M, NEURE L, et al.: Use of immunohistologic in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
92. BREBAN M, GOMBERT B, AMOR B, DOUGADOS M: Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 1999; 42: 580-1.
93. ERAVELLY J, WATERS MFR: Thalidomide in Weber-Christian disease. Lancet 1977; 1: 251.
94. BAERT FJ, RUTGEERTS PJ: Medical therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2000; 2: 446-50.
95. FACCHINI S, CANDUSSO M, MARTELOSSI S, LIUBICH M, PANFILI E, VENTURA A: Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr 2001; 32:178-81.
96. WATERS MFR, LAING ABG, AMBIKAPATHY A, LENNARD-JONES JE: Treatment of ulcerative colitis with Thalidomide. Br Med J 1979; 1: 792.
97. BAUDITZ J, WEDEL S, LOCHS H: Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002; 50: 196-200.
98. FLORENCE AL: Is thalidomide to blame? BMJ 1960; 2: 1954.
99. COHEN S: Thalidomide polyneuropathy. N Engl J Med 1962; 266: 1208.
100. FULLERTON PM, O'SULLIVAN DJ: Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry 1968; 31: 543-51.
101. OCHONISKY S, VERROUST J, BASTUJIGARIN S, GHERARDI R, REVUZ J: Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66-9.
102. SHESKIN J: Therapeutische Erfahrungen uber den Einfluss des Thalidomids bei der Lepra-Reaktion. Hautarzt 1975; 26: 1-5.
103. WULFF CH, HOYER H, ABSOE-HANSEN G, BRODTHAGEN H: Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112: 475-80.
104. GUNZLER V: Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Saf 1992; 7: 116-34.
105. WOODCOCK J: Supervisory Review of NDA 20-785. Washington (DC), Food and Drug Administration, 1998.
106. Thalidomide: Potential Benefits and Risks. Open public scientific workshop. Washington, DC, National Institutes of Health, 1997.
107. ROUTLEDGE P: 150 years of pharmacovigilance. Lancet 1998; 351: 1200-1.
108. PEUCKMANN V, FISCH M, BRUERA E: Potential novel uses of thalidomide: focus on palliative care. Drugs 2000; 60: 273-92.
109. MCBRIDE WG: Thalidomide may be a mutagen. BMJ 1994; 308: 1635-6.
110. ASHBY J: Thalidomide is not a mutagen. Nature 1997; 389: 118.
111. SMITHELLS D: Does thalidomide cause second generation birth defects? Drug Saf 1999; 19: 330-41.
112. Thalomid (Thalidomide). Prescribing information, Celgene Corporation, 1998
113. FLAGEUL B, WALLACH D, CAVELIER-BALLOY B, BACHELEZ H, CARSUZAA F, DUBERTRET L: Thalidomide and thrombosis. Ann Dermatol Venereol 2000; 127: 171-4.
114. POWELL RJ, GARDNER-MEDWIN NJM: Guideline for the clinical use and dispensing of Thalidomide. Postgrad Med J 1994; 70: 901-4.
115. ZELDIS JB, WILLIAMS BA, THOMAS SD, ELSAYED ME: S.T.E.PS.: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999; 21: 319-30.
116. RAO DG, KANE NM, OWARE A: Thalidomide neuropathy: Role of F-wave monitoring. Muscle Nerve 2000; 23: 1301-2.
117. IYER CG, LANGUILLON J, RAMANUJAM K et al.: WHO coordinate short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull WHO 1971; 45: 719-32.
118. MATTOS O: Prurigo nodular de hyde tratado con talidomida. Bol Div Nac Lepra 1973; 32:71-7.
119. SHESKIN J: Zur therapie der prurigo nodularis hyde mit thalidomide. Hautarzt 1975; 26: 215.
120. VAN DEN BROEK H: Treatment of prurigo nodularis with thalidomide. Arch Dermatol 1980; 116: 571-2.
121. VENENCIE PY, SAURAT JH: Pyoderma gangrenosum in a child. Treatment with thalidomide. Ann Pediatr (Paris) 1982; 29: 67-9.
122. FEDERMAN GL, FEDERMAN DG: Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc 2000; 75: 842-4.
123. ROUSSEAU L, BEYLOT-BARRY M, DOUTRE MS, BEYLOT C: Cutaneous sarcoidosis successfully treated with low dose of thalidomide. Arch Dermatol 1998; 134: 1045-6.
124. CARLESIM0 M, GIUSTINI S, ROSSI A, BONACCORSI P, CALVIERI S: Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866-9.
125. OLIVER SJ, MOREIRA A, KAPLAN G: Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000; 97: 109-20.
126. FIELD EO, GIBBS JE, TUCKER DF, HELLMANN K: Effect of thalidomide on the graft versus host reaction. Nature 1966; 211: 1308-10.
127. VOGELSANG GB, FARMER ER, HESS AD et al.: Thalidomide for the treatment of GVHD. N Engl J Med 1992; 326: 1055-8.
128. ROVELLI A, ARRIGO C, NESI F et al.: The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998; 21: 577-81.
129. WALLACH FR, MURRAY HW: Thalidomide in painful AIDS-associated proctitis. J Infect Dis 1992; 166: 939.
130. GEHANNO P, BARRY B, DEPONDT J et al.: Mouth and pharyngeal hyperalgesic syndromes in AIDS. Ann Otolaryngol Chir Cervicofac 1990; 107: 311-3.